Influence of insulin resistance on long-term outcomes in patients with coronary artery disease after sirolimus-eluting stent implantation

Chinese Medical Journal

Volumn 123, Issue 6, 2010, Pages 651-657

  Zhao, Liang Ping ^a   Lü, An Kang ^a   Shen, Wei Feng ^a   Liu, Hai Feng ^a   Ma, Xiao Ye ^a   Fan, Xiao Ming ^a   Zhang, Qi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Coronary artery disease; Insulin resistance; Long term prognosis; Sirolimus eluting stent

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN;

AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; SURVIVAL TIME;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 77949810054     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.06.003     Document Type: Article

References (42)

1. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992; 231: 25-30.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
3. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
4. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects. Diabetes 1998; 47: 793-800.
5. Yanase M, Takatsu F, Tagawa T, Arai K, Kovasu M, Horibe H, et al. Insulin resistance and fasting hyperinsulinemia are risk factors for new cardiovascular events in patients with prior coronary artery disease and normal glucose tolerance. Circ J 2004; 68: 47-52.
6. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 2007; 49: 2112-2119.
7. Marso SP, Murphy JW, House JA, Safley DM, Harris WS. Metabolic syndrome-mediated inflammation following elective percutaneous coronary intervention. Diab Vasc Dis Res 2005; 2: 31-36.
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
9. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio heart study. Diabetes Care 1997; 20: 1087-1092.
10. Li G, Hu Y, Yang W, Jiang Y, Wang J, Xiao J, et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Res Clin Pract 2002; 58: 193-200.
11. Zhang RY, Ni JW, Zhang JS, Hu J, Yang ZK, Zhang Q, et al. Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention. Chin Med J 2006; 119: 1176-1181.
12. Pan XR, Yang WY, Liu J. The prevalence rate of diabetes and its risk factors in China 1994. Chin J Intern Med (Chin) 1997; 6: 384-389.
13. Pu LJ, Lu L, Shen WF, Zhang Q, Zhang RY, Zhang JS, et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 2007; 71: 1067-1073.
14. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
15. Karabulut A, Iltumur K, Toprak N, Tuzcu AK, Kara IH, Kaplan A, et al. Insulin response to oral glucose loading and coronary artery disease in nondiabetics. Int Heart J 2005; 46: 761-770.
16. Nakamura Y, Saitoh S, Takagi S, Ohnishi H, Chiba Y, Kato N, et al. Impact of abnormal glucose tolerance, hypertension and other risk factors on coronary artery disease. Circ J 2007; 71: 20-25.
17. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
18. Rewers M, Zaccaro D, D'Agostino R, Haffner S, Saad MF, Selby JV, et al. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27: 781-787.
19. Young MH, Jeng CY, Sheu WH, Shieh SM, Fuh MM, Chen YD, et al. Insulin resistance, glucose intolerance, hyperinsulinemia and dyslipidemia in patients with angiographically demonstrated coronary artery disease. Am J Cardiol 1993; 72: 458-460.
20. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, et al. Mechanisms of hepatic artery very low density lipoprotein overproduction in insulin resistance: evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000; 275: 8416-8425.
21. Potenza MA, Marasciulo FL, Chieppa DM, Briqiani GS, Formoso G, Quon MJ, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol 2005; 289: H813-H822.
22. Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48: 2531-2538.
23. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185: 70-77.
24. Mizuno T, Matsui H, Imamura A, Numaguchi Y, Sakai K, Murohara T, et al. Insulin resistance increases circulating malondialdehyde-modified LDL and impairs endothelial function in healthy young men. Int J Cardiol 2004; 97: 455-461.
25. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992; 231: 25-30.
26. Yarnell JW, Sweetnam PM, Marks V, Teale JD, Bolton CH. Insulin in ischemic heart disease: are associations explained by triglyceride concentrations: the Caerpholly prospective study. Br Heart J 1994; 171: 293-296.
27. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one year follow-up of the e-Cypher registry. Circulation 2006; 113: 1434-1441.
28. Lopez-Minguez JR, Nogales JM, Morales A, Alonso R, Gonzalez R, Merchan A. Clinical and angiographic follow-up in patients with Cypher or Taxus stents in populations with high percentage of trial excluded lesions. Cardiovasc Revasc Med 2005; 6: 92-98.
29. Lazzeri C, Sori A, Chiostri M, Gensini GF, Valente S. Prognostic role of insulin resistance as assessed by homeostatic model assessment index in the acute phase of myocardial infarction in nondiabetic patients submitted to percutaneous coronary intervention. Eur J Anaesthesiol 2009; 1: 1-7.
30. Yun KH, Jeong MH, Kim KH, Hong YJ, Park HW, Kim JH, et al. The effect of insulin resistance on prognosis of non-diabetic patients who underwent percutaneous coronary intervention. J Korean Med Sci 2006; 21: 212-216.
31. Zhao FH, Chen YD, Song XT, Pan WQ, Jin ZN, Yuan F, et al. Predictive factors of recurrent angina after acute coronary syndrome: the global registry acute coronary events from China (Sino-GRACE). Chin Med J 2008; 121: 12-16.
32. Feuvre CL, Montalescot G, Rosey G, Collet JP, Beygui F, Choussat R, et al. Predictive factors of cardiac events after implantation of sirolimus-eluting stents for treatment of in-stent restenosis. Int J Cardiol 2006; 109: 207-212.
33. Paudel B, Xuan G, Chun Z. Analysis of clinical factors affecting the restenosis following percutaneous coronary intervention. Nepal Med Coll J 2005; 7: 101-106.
34. Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res 2006; 118: 487-493.
35. Jacopo G, Elisabetta V, Silverio S, Massimiliano M, Sergio B, Grazia AM, et al. Identification of platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary intervention predicts in stent thrombosis. Thromb Res 2007; 121: 407-412.
36. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 13: 1888-1904.
37. Nishimura M, Tokoro T, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S, et al. Association of insulin resistance with de novo coronary stenosis after percutaneous coronary artery intervention in hemodialysis patients. Nephron Clin Pract 2008; 109: 9-17.
38. Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: The obesity paradox? J Am Coll Cardiol 2002; 39: 578-584.
39. Park MW, Par JH, Yoon SK, Baek JY, Koh YS, Shin DI, et al. Progression of untreated nonculprit coronary lesions: long-term clinically-driven PCI rate and associated independent predictors. Circulation 2008; 118: S747-S748.
40. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691-696.
41. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001; 104: 342-345.
42. de Jongh RT, Serné EH, IJzerman RG, de Vries G, Stehouwer CD. Impaired microvascular function in obesity implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004; 109: 2529-2535.